1. Introduction

Biomarker Immigration Accountability Doctrine and Governance is a developing interdisciplinary legal concept concerning the use of biological indicators, genetic information, medical test results, and other health-related data in immigration decisions.

Biomarkers are measurable biological characteristics that can indicate normal biological processes, diseases, physiological conditions, or responses to medical treatment. Examples include blood-test results, hormone levels, immune-system indicators, genetic variants, and molecular signatures.

In immigration administration, biomarker information might be relevant to medical admissibility examinations, infectious-disease screening, public-health assessments, disability-related accommodation, or the evaluation of medical evidence submitted by an applicant.

However, biomarkers can also create serious legal concerns if immigration authorities use them to infer an individual's future health, employability, life expectancy, genetic ancestry, or potential burden on public services without adequate scientific evidence or legal justification.

The central legal question is: To what extent may immigration authorities collect, interpret, share, and rely on biological information when deciding whether a person may enter, remain in, or obtain permanent residence in a country?

There is no universally established legal doctrine bearing this exact title. Rather, the concept can be developed from existing principles of constitutional law, immigration law, medical privacy, administrative accountability, anti-discrimination law, data protection, and procedural fairness.

The following analysis explains these principles through relevant judicial decisions, with particular attention to India, the United States, the United Kingdom, Canada, Australia, and European human-rights law.

2. Meaning and Scope of the Doctrine

The proposed doctrine can be divided into five interconnected legal principles.

A. Biomarker legality

Immigration authorities should collect or use biomarker information only when authorised by applicable law and when the collection serves a legitimate immigration or public-health purpose.

For example, a legally authorised medical examination intended to identify a communicable disease presents a different legal question from an unofficial genetic test intended to predict whether an applicant will become ill in twenty years.

The legality of the examination depends on the applicable statute, the purpose of collection, the nature of the test, and the safeguards governing the resulting information.

B. Scientific reliability

Biomarker evidence should not be treated as conclusive merely because it is scientific or generated by a laboratory.

A decision-maker should consider:

• Whether the test has been scientifically validated.
• Whether the result is relevant to the statutory immigration criterion.
• Whether the test measures a current condition or merely predicts a possible future condition.
• Whether the result has been interpreted by a qualified professional.
• Whether alternative explanations, uncertainty, or false-positive results have been considered.

A biomarker associated with a disease does not necessarily establish that an individual has that disease. Likewise, a genetic predisposition does not establish that the person will develop a particular condition.

C. Privacy and informational autonomy

Biological information may reveal intimate details about an individual's health, genetic characteristics, family relationships, or reproductive status.

Immigration authorities must therefore consider applicable privacy and data-protection law, including rules on collection, retention, disclosure, security, and secondary use.

The fact that an applicant must undergo a legally required medical examination does not automatically authorise unlimited use of the resulting information.

D. Equality and non-discrimination

Biomarker-based decisions may raise discrimination concerns when authorities use biological characteristics as substitutes for nationality, race, ancestry, disability, or perceived social worth.

For example, rejecting an applicant solely because of a genetic predisposition to a future illness could raise questions about scientific validity, proportionality, disability discrimination, and equal treatment.

Whether a particular decision is unlawful depends on the governing jurisdiction and the relevant statutory exceptions.

E. Accountability and review

Immigration authorities should be able to explain the legal and evidentiary basis of biomarker-dependent decisions.

Depending on the applicable law, accountability may involve administrative reconsideration, access to reasons, independent medical review, judicial review, correction of inaccurate data, or a challenge to discriminatory treatment.

The proposed doctrine therefore seeks to prevent biological information from becoming an unchallengeable substitute for lawful decision-making.

3. Biomarker Immigration Governance in India

A. Constitutional framework

In India, immigration and citizenship decisions operate within a constitutional framework that distinguishes between the rights of citizens and those available to all persons.

Relevant provisions include:

• Article 14: Equality before the law and equal protection of the laws.
• Article 20: Protection against specified forms of criminal prosecution and punishment.
• Article 21: Protection of life and personal liberty.
• Article 32: Right to approach the Supreme Court for enforcement of fundamental rights.
• Article 226: High Courts' writ jurisdiction.
• Article 51(c): Promotion of respect for international law and treaty obligations.

Articles 14 and 21 are particularly important because their protections extend to persons generally, although the precise application of each right depends on the circumstances.

Article 19, by contrast, grants its specified freedoms to citizens. A foreign national cannot automatically invoke every constitutional protection available to an Indian citizen.

Consequently, a foreign national challenging an invasive medical examination, unjustified disclosure of medical information, or arbitrary immigration decision may need to rely on the constitutional provision and statutory protections applicable to their circumstances.

B. Justice K.S. Puttaswamy v. Union of India (2017)

Citation: (2017) 10 SCC 1.

Court: Supreme Court of India.

This nine-judge Constitution Bench decision recognised privacy as a fundamental right protected by the Constitution.

The Court connected privacy with dignity, personal autonomy, liberty, and control over personal information. It also established that governmental interference with privacy must satisfy constitutional requirements, including legality, a legitimate state aim, and proportionality. Sci API

Application to biomarker-based immigration

Suppose an immigration authority proposes to collect genetic information from visa applicants to predict their future susceptibility to disease.

The constitutional analysis would include the following questions:

1. Is the collection authorised by law?
2. Does the collection pursue a legitimate governmental purpose?
3. Is genetic testing necessary to achieve that purpose?
4. Could a less intrusive medical examination achieve the same objective?
5. Are the data securely stored, retained only as justified, and protected against unauthorised disclosure?
6. Can the affected person challenge an adverse decision?

The decision does not automatically prohibit all medical examinations of foreign nationals. Rather, it supplies a constitutional framework for assessing state interference with privacy.

Legal significance: Puttaswamy supports the argument that sensitive biomarker collection cannot be justified solely by administrative convenience.

C. Mr. X v. Hospital Z (1998)

Citation: (1998) 8 SCC 296.

Court: Supreme Court of India.

This decision concerned the disclosure of a patient's HIV-positive status in circumstances involving an intended marriage. The Court considered medical confidentiality alongside competing interests in protecting another person's health.

The case demonstrates that medical confidentiality is important but not absolute in every circumstance.

Application to immigration governance

The decision is relevant when an immigration authority seeks to disclose an applicant's biomarker results to another government department, a prospective sponsor, an employer, or a public-health authority.

The legal question is whether disclosure is supported by applicable law and justified by the circumstances, rather than whether the information is medically interesting or administratively convenient.

For example, a lawful public-health notification may be treated differently from the unrestricted disclosure of an applicant's genetic profile to unrelated agencies.

However, Mr. X is not a direct ruling on immigration screening or genetic biomarkers. Its relevance is by analogy to the principles of medical confidentiality and competing public interests.

D. Judicial review of biomarker-based immigration decisions

Where an immigration decision affects a person's legal status, judicial review may examine whether the authority:

• Acted within its statutory powers.
• Followed the required procedure.
• Considered relevant evidence.
• Avoided reliance on irrelevant considerations.
• Reached a decision that is legally sustainable.
• Complied with applicable constitutional and statutory protections.

A court would not necessarily substitute its own medical opinion for that of a qualified specialist. Nevertheless, scientific expertise does not exempt an administrative decision from judicial scrutiny.

Important limitation: The cases discussed above do not establish a specific Indian constitutional right to enter or settle in India for every foreign national. Nor do they establish a categorical prohibition on using biomarkers in immigration procedures.

4. Biomarker Immigration Governance in Canada

Canada provides a particularly useful jurisdiction for understanding the relationship between medical evidence, immigration admissibility, disability, and administrative accountability.

A. Statutory framework

Under section 38 of Canada's Immigration and Refugee Protection Act, a foreign national may be inadmissible on health grounds where their health condition:

1. Is likely to endanger public health.
2. Is likely to endanger public safety.
3. Might reasonably be expected to cause excessive demand on health or social services, subject to statutory exceptions.

The applicable regulations govern medical assessments and the factors relevant to such decisions. CanLII

Biomarkers may form part of the evidence establishing a medical condition. However, a laboratory result and the legal conclusion of inadmissibility are distinct matters.

An immigration officer must apply the relevant statutory test rather than automatically treating every abnormal biomarker as a ground for refusal.

B. Hilewitz v. Canada (Minister of Citizenship and Immigration) (2005)

Citation: 2005 SCC 57, [2005] 2 SCR 706.

Court: Supreme Court of Canada.

This leading case was decided together with De Jong v. Canada (Minister of Citizenship and Immigration).

The litigation concerned medical inadmissibility and the assessment of the likely demands that applicants with intellectual disabilities would place on Canadian health and social services.

The Court rejected an approach that relied on a diagnosis or classification without adequately examining the individual circumstances relevant to the statutory test.

The decision is widely associated with the importance of individualised assessments in medical inadmissibility cases.

Application to biomarker governance

Suppose a biomarker identifies an applicant as having an increased probability of developing a neurological condition.

An authority should distinguish between:

• A confirmed present condition.
• A statistical probability of future illness.
• The severity and likely progression of the condition.
• The actual consequences relevant to the immigration statute.
• Any individual circumstances that the governing legal framework requires it to consider.

The biomarker cannot automatically determine the outcome. Its legal significance depends on what it establishes and how that evidence relates to the statutory criteria.

Principle: Individualised assessment is preferable to a decision based solely on a medical label.

The precise factors that an immigration officer may consider must still be determined under the current legislation and regulations.

C. Chesters v. Canada (Minister of Citizenship and Immigration) (2002)

Citation: 2002 FCT 727; [2003] 1 F.C. 361.

Court: Federal Court of Canada, Trial Division.

The applicant, who had multiple sclerosis, challenged a medical inadmissibility decision based on the possibility that her condition would create excessive demands on health and social services.

The Court upheld the decision under the legal framework then applicable, finding no established violation of the constitutional provisions relied upon by the applicant. The case also addressed the fairness and structure of the medical assessment process. epe.lac-bac.gc.ca

Application to biomarker governance

This decision illustrates the importance of distinguishing between the existence of a medical condition and the legal consequences attached to it.

For biomarker-based decisions, an authority should identify the relevant legal criterion and explain how the evidence supports the conclusion reached.

A test result that identifies a medical risk should not be treated as sufficient by itself unless the applicable legal test makes that evidence sufficient.

The case must also be understood in its historical statutory context: it does not establish that every present-day medical inadmissibility decision based on disability or disease will be lawful.

D. Rashid v. Canada (Minister of Citizenship and Immigration) (2010)

Citation: 2010 FC 157.

Court: Federal Court of Canada.

The applicant was HIV-positive but asymptomatic. His application for permanent residence was refused on medical inadmissibility grounds involving the anticipated costs of medication and health services.

The Federal Court dismissed his judicial-review application, finding no reviewable error in the decision on the evidence before it. The case illustrates the practical importance of the medical officer's assessment, the applicant's supporting evidence, and the statutory framework. vLex

Application to biomarker governance

A positive biomarker result may establish the presence of a particular biological condition, but the immigration consequences depend on the governing statute.

Where the legal test requires a prediction about future health-service demands, the decision should not confuse the diagnosis itself with the predicted consequences.

The case is not authority for treating every positive HIV test, or every biomarker associated with a chronic condition, as an automatic basis for exclusion.

5. Genetic Information and Immigration Enforcement in Canada

Office of the Privacy Commissioner of Canada: CBSA genetic genealogy investigation

Report: CBSA's use of commercial genetic genealogy in a deportation case contravenes the Privacy Act.

This is an especially relevant regulatory investigation because it concerns the use of genetic information to establish nationality during immigration enforcement.

The Canada Border Services Agency (CBSA) used commercial genetic genealogy services in an attempt to determine the nationality of a person subject to removal proceedings.

The Office of the Privacy Commissioner found that the CBSA's collection and disclosure practices breached provisions of the federal Privacy Act. Among other findings, it concluded that the agency had failed to provide key information about the commercial genetic genealogy service, making the person's authorisation invalid in the circumstances. It also found unlawful disclosure of certain personal information and inadequate transparency concerning genetic information collected from potential genetic relatives. Office of the Privacy Commissioner

Legal significance

This investigation reveals several important governance principles.

First, biological information can be more revealing than ordinary identity documents.

Genetic information may reveal family relationships and potentially sensitive information about people who are not themselves immigration applicants.

Second, the existence of a general immigration-enforcement power does not eliminate privacy obligations.

The investigation accepted that the applicable immigration legislation provided authority broad enough to encompass the DNA collection at issue. Nevertheless, the agency's practices still breached other requirements of the Privacy Act.

Third, authorisation and meaningful understanding are distinct issues.

Where a person is detained or faces removal, the practical circumstances of obtaining authorisation require careful examination. In this case, the Commission's finding concerning authorisation turned on the information supplied about the commercial service.

Fourth, transparency must account for affected third parties.

A genetic investigation can collect information relating to people who are not themselves subject to removal proceedings. A governance system must address these indirect effects.

Fifth, genetic genealogy is not the same as ordinary medical biomarker testing.

The investigation directly concerns genetic identification and ancestry-related information, not a conventional medical test used to diagnose disease. It is nevertheless highly relevant to the broader accountability principles governing biological information in immigration administration.

The investigation was an official privacy-regulator finding, not a judicial judgment. It should therefore be cited as a regulatory authority rather than represented as a court precedent.

6. Biomarker Immigration Governance in the United States

The United States provides an important example of how genetic information can be used in immigration decisions, particularly in family-based visa petitions and the verification of biological relationships.

A. Statutory framework

The principal legal framework includes the Immigration and Nationality Act, applicable federal regulations, administrative guidance, and constitutional due-process principles.

Biological evidence may be used to establish whether a claimed parent-child or sibling relationship exists. However, DNA evidence used to establish family relationships is different from medical biomarker evidence used to predict disease.

The legal distinction matters because each type of evidence serves a different purpose.

For example:

• Relationship testing: Determines whether biological evidence supports a claimed family relationship.
• Disease biomarkers: May indicate the presence or likelihood of a medical condition.
• Genetic ancestry testing: May produce information about genetic ancestry, but does not conclusively establish nationality or citizenship.
• Biometric identification: Uses biological or physical characteristics to identify an individual.

An immigration authority should not assume that evidence relevant to one of these purposes necessarily establishes another.

B. Matter of Ruzku (2016)

Citation: 26 I&N Dec. 731 (BIA 2016).

Court: Board of Immigration Appeals, United States.

This administrative immigration precedent concerned DNA evidence offered to establish a claimed sibling relationship.

The Board recognised the evidentiary value of sufficiently strong sibling DNA results while emphasising that other evidence should also be considered in the totality of the circumstances.

The decision is significant because it illustrates that genetic evidence must be interpreted in light of the relationship being investigated and the applicable evidentiary standards. Subsequent US Citizenship and Immigration Services guidance addressed the interpretation of full-sibling and half-sibling test results. USCIS

Application to biomarker immigration accountability

Suppose an applicant submits a genetic report suggesting a particular biological relationship.

A responsible decision-maker should consider:

1. The scientific validity of the test.
2. The probability reported by the laboratory.
3. Whether the result is conclusive or inconclusive under the applicable standard.
4. Other documentary and testimonial evidence.
5. Any limitations in the test's interpretation.

The broader lesson is that scientific evidence should be evaluated according to its actual evidentiary meaning, rather than treated as an infallible determination.

Limitation: Matter of Ruzku concerns biological relationships, not medical inadmissibility based on disease biomarkers.

C. Muthana v. Mullin (2026)

Citation: No. 24-2320, United States Court of Appeals for the Seventh Circuit, decided April 1, 2026.

This case arose from family-based immigration petitions and disputes concerning proof of biological relationships and the government's handling of the petition process.

The litigation illustrates that disputes involving DNA evidence may raise questions beyond laboratory accuracy, including procedural fairness, notice, administrative delay, and the opportunity to respond to an adverse immigration decision. Justia Law

Relevance to the proposed doctrine

A biomarker-based immigration decision should be assessed not only by asking whether the underlying scientific evidence is accurate, but also by asking whether the decision-making process was lawful.

For example, if an authority relies on a genetic report to reject an application, procedural accountability may require consideration of whether the applicant was properly notified, whether the applicable evidentiary standard was applied, and whether a legally available review procedure was respected.

The precise holding of Muthana must be applied to its actual procedural and statutory context; it is not a general judicial prohibition on DNA testing in immigration cases.

D. Muthana et al. v. Mayorkas et al. (2023)

Citation: No. 22-cv-02200, United States District Court for the Northern District of Illinois, November 30, 2023.

This earlier stage of the litigation involved allegations concerning DNA testing in family-based immigration petitions, due process, and the handling of a denial notice.

The district court denied the government's motion to dismiss. That ruling concerned whether the claims could proceed at that stage; it should not be mistaken for a final determination that every alleged constitutional violation occurred. The subsequent appeal was decided in Muthana v. Mullin in 2026. Justia Law

Legal significance

The litigation demonstrates why genetic evidence must be considered alongside procedural safeguards.

An applicant may dispute not only the interpretation of DNA evidence but also the process through which that evidence was requested, assessed, and used.

This is particularly important where an adverse decision affects family reunification.

7. European Human-Rights Principles: Genetic and Medical Privacy

European human-rights jurisprudence provides important principles for evaluating government collection and retention of sensitive biological information.

Although the cases discussed below do not directly establish rules for biomarker-based immigration screening, they offer useful guidance on privacy, proportionality, and safeguards.

A. S. and Marper v. United Kingdom (2008)

Citation: Applications Nos. 30562/04 and 30566/04, Grand Chamber, European Court of Human Rights, 4 December 2008.

Legal provision: Article 8 of the European Convention on Human Rights.

The applicants challenged the retention of their fingerprints, cellular samples, and DNA profiles after criminal proceedings had ended without conviction.

The Court found a violation of Article 8 in relation to the retention of their biological samples and DNA profiles.

It emphasised the sensitive nature of genetic information, including its capacity to reveal health information and genetic relationships. The retention of such information therefore constituted an interference with private life. HUDOC

Application to immigration governance

Consider a system that collects biological samples from immigration applicants and retains them indefinitely, even after the original immigration purpose has ended.

The principles in S. and Marper support scrutiny of:

• The legal basis for collecting the samples.
• The purposes for which the samples may be used.
• The duration of retention.
• The possibility of future analysis for unrelated purposes.
• The safeguards governing access and disclosure.

The decision does not automatically prohibit immigration authorities from collecting DNA or other biological information. Its significance lies in recognising that the nature and retention of genetic information can substantially interfere with privacy.

B. Z v. Finland (1997)

Citation: Application No. 22009/93, European Court of Human Rights, 25 February 1997.

Legal provision: Article 8 of the European Convention on Human Rights.

This case concerned the confidentiality of medical information, including information about HIV infection, in judicial proceedings.

The Court emphasised the importance of protecting confidential medical information and found a violation in relation to the disclosure and publication of sensitive information in the circumstances of the case. HUDOC

Application to biomarker immigration governance

A medical examination may produce information that is relevant to a particular immigration decision but inappropriate for unrestricted disclosure.

For example, an immigration authority might lawfully need to establish whether a specified public-health criterion is satisfied. That does not necessarily justify distributing the applicant's complete medical history or genetic profile to every department involved in immigration administration.

The relevant distinction is between the information reasonably needed for a lawful decision and the broader body of sensitive information that a biological test may reveal.

C. Beghal v. United Kingdom (2019)

Citation: Application No. 4755/16, European Court of Human Rights, 28 February 2019.

Legal provision: Article 8 of the European Convention on Human Rights.

The case concerned the exercise of coercive examination and questioning powers at an airport under counter-terrorism legislation.

The Court considered the interference with private life associated with those powers and the legal safeguards governing their exercise.

Although the case did not concern biomarker testing, it is relevant by analogy to the scrutiny of coercive powers exercised at borders. HUDOC

Application

An immigration authority's power to conduct examinations at a border should not be confused with unlimited authority to collect intimate biological information.

Where a biomarker examination involves a substantial interference with privacy or bodily autonomy, the legal basis, purpose, scope, and safeguards should be examined under the applicable domestic and international law.

8. The United Kingdom: Medical Evidence and Immigration Detention

Medical information may also affect decisions about immigration detention, vulnerability, and removal.

Medical Justice v. Secretary of State for the Home Department

Case reference: UK Supreme Court, UKSC/2025/0065.

The litigation concerns a challenge to a policy governing second medical opinions in immigration detention, particularly where detainees rely on medico-legal reports to establish vulnerability under the government's adults-at-risk policy.

The case raises questions about statutory compliance and the common-law duty to consult. As recorded on the Supreme Court's case page, permission to appeal had been lodged; the cited page does not establish a final Supreme Court judgment on the merits. Supreme Court UK

Relevance to biomarker governance

The dispute illustrates that medical evidence used in immigration administration raises questions about the quality and independence of expert assessment.

Where an immigration authority questions medical evidence, a sound governance process should distinguish between:

• A legitimate request for clarification or a second opinion.
• An unexplained preference for one medical opinion over another.
• Failure to consider relevant medical evidence.
• A procedure inconsistent with applicable legislation or published policy.

Biomarker evidence should be treated with the same general concern for procedural integrity, while recognising that a dispute over medical vulnerability is not identical to a dispute over the scientific validity of a biomarker.

9. The Central Governance Problem: Biomarkers Versus Legal Conclusions

A major challenge arises when an immigration authority treats a biological indicator as if it independently determines a person's legal status.

Consider four hypothetical situations.

These examples demonstrate a fundamental distinction:

Scientific evidence describes or predicts biological facts; immigration law determines the legal consequences that may legitimately follow from those facts.

A biomarker should not independently become a legal rule unless the governing legislation makes the relevant biological characteristic legally material and the decision complies with applicable safeguards.

10. The Accountability Structure

A practical Biomarker Immigration Accountability Doctrine can be organised into six stages.

Stage 1: Legal authorisation

The authority must identify the legal provision that permits the collection or use of the relevant information.

A general power to examine applicants does not necessarily answer every question concerning genetic testing, retention of biological samples, or disclosure to third parties.

The more intrusive the procedure, the more carefully the legal authority and safeguards should be examined.

Stage 2: Purpose limitation

The authority should define why the biomarker is required.

For example, a DNA test requested to establish a claimed parent-child relationship should not automatically become a general-purpose medical or ancestry investigation.

Where the applicable law permits secondary use, that use must still comply with the relevant legal requirements.

Stage 3: Scientific validation

The authority should establish that the test is suitable for the question being asked.

Relevant considerations include sensitivity, specificity, false-positive rates, limitations of interpretation, and the strength of the relationship between the biomarker and the statutory criterion.

A predictive marker should not be confused with proof of a present medical condition.

Stage 4: Individualised assessment

The decision-maker should consider the applicant's actual circumstances and the evidence required by the applicable legal test.

A statistically elevated risk does not automatically establish that an applicant is dangerous, will require particular services, or will develop a specific illness.

Where the statute requires an individualised assessment, a decision based exclusively on a broad biological classification may be legally defective.

Stage 5: Procedural fairness

Depending on the applicable legal framework, procedural safeguards may include:

• Notice of the adverse evidence.
• An opportunity to correct factual errors.
• Access to relevant reasons for the decision.
• Independent medical or scientific review where available.
• Consideration of competing evidence.
• Access to administrative or judicial review.

The exact safeguards depend on the jurisdiction, type of proceeding, and legal status of the applicant.

Stage 6: Data governance and accountability

The authority should establish appropriate controls over the resulting information.

These may include:

• Secure storage.
• Restricted access.
• Defined retention periods.
• Rules governing disclosure.
• Documentation of the decision-making process.
• Procedures for correcting inaccurate information.
• Independent oversight and complaint mechanisms.

The Canadian Privacy Commissioner’s investigation into genetic genealogy is particularly instructive because it demonstrates how genetic information can affect both the person under investigation and third parties whose genetic profiles become relevant to the search. Office of the Privacy Commissioner

11. Biomarker-Based Immigration Discrimination

One of the most serious potential problems is the use of biological information as a proxy for social or economic judgments about applicants.

A. Genetic predisposition

A genetic variant may indicate an increased probability of developing a condition, but it does not necessarily establish that the condition will develop.

Using such a variant as an automatic basis for exclusion could raise questions about the relevance of the evidence, the proportionality of the decision, and the applicable anti-discrimination protections.

B. Disability and medical conditions

An applicant's disability or medical diagnosis should not automatically be equated with dangerousness, inability to contribute to society, or inevitable reliance on public services.

The legality of a medical inadmissibility decision depends on the governing immigration legislation and applicable human-rights protections.

The Canadian cases Hilewitz and Chesters illustrate that medical inadmissibility disputes require analysis of the statutory framework and the evidence supporting the individual decision.

C. Ancestry and nationality

Genetic ancestry is not identical to legal nationality.

A genetic report might provide information about ancestral relationships or population similarities, but nationality and citizenship are legal statuses determined under applicable law.

Authorities should therefore be cautious about treating genetic ancestry as conclusive proof of nationality, particularly where historical migration, adoption, mixed ancestry, and the limitations of genetic reference databases may complicate interpretation.

D. Algorithmic profiling

An automated system might combine biomarkers with age, nationality, travel history, or other data to assign an immigration risk score.

Such a score is not necessarily reliable merely because it is generated computationally.

A legally accountable system should be capable of explaining the score's relevance to the statutory decision, identifying material errors, and allowing meaningful review where required by law.

The governing law may differ depending on whether the system is used for medical screening, identity verification, security assessment, or visa adjudication.

12. International Human-Rights Considerations

Several international instruments may be relevant to biomarker immigration governance.

A. Universal Declaration of Human Rights

Article 12 protects against arbitrary interference with privacy, family, home, or correspondence.

Article 7 addresses equality before the law and equal protection against discrimination.

These provisions supply important normative principles, although their domestic enforceability depends on the applicable legal system.

B. International Covenant on Civil and Political Rights

Article 17 addresses arbitrary or unlawful interference with privacy, family, home, and correspondence.

Article 26 provides for equality before the law and equal protection without discrimination.

The application of these provisions to a particular immigration decision depends on the state's treaty obligations, the relevant facts, and the interpretation of the Covenant.

C. Convention on the Rights of Persons with Disabilities

The Convention on the Rights of Persons with Disabilities provides a framework for equality, non-discrimination, accessibility, and respect for the rights of persons with disabilities.

Its relevance to immigration screening depends on the applicable provisions, the state's obligations, and the relationship between the immigration measure and disability-related rights.

D. Convention on Human Rights and Biomedicine

The Council of Europe's Convention on Human Rights and Biomedicine contains principles relating to human dignity, consent, and genetic testing. Its applicability depends on whether the relevant state is bound by the Convention and on the scope of the particular provisions.

These instruments do not collectively create a universal rule prohibiting all biomarker testing in immigration. Rather, they help identify the human-rights interests that may need to be balanced against legitimate governmental objectives.

13. A Proposed Legal Test for Biomarker Immigration Decisions

The following is a proposed analytical framework, not a test already adopted by a court under the name Biomarker Immigration Accountability Doctrine.

A reviewing authority could ask seven questions.

1. Authority: Is there a valid legal basis for collecting and using the biomarker?

2. Purpose: Is the biological information relevant to a legitimate immigration or public-health objective?

3. Reliability: Is the test scientifically suitable for the proposition the authority seeks to establish?

4. Necessity: Is the collection or use of the information necessary under the applicable legal standard?

5. Proportionality: Is the interference with privacy, bodily autonomy, family life, or equality justified by the legitimate objective?

6. Fairness: Has the applicant received the procedural protections required by law, including a meaningful opportunity to challenge material adverse evidence where applicable?

7. Accountability: Are there adequate mechanisms for correcting errors, restricting secondary use, reviewing decisions, and addressing unlawful conduct?

This framework draws on the principles of Puttaswamy, Hilewitz, S. and Marper, and the Canadian privacy regulator's genetic-genealogy investigation.

It is an analytical synthesis of existing legal authorities, not a statement that those authorities collectively established a single binding seven-part test.

14. Remedies for Unlawful Biomarker-Based Immigration Decisions

Available remedies depend on the jurisdiction, the kind of decision, and the applicant's legal position.

Potential remedies include the following.

Not every error results in the same remedy. A court may set aside a decision, require reconsideration, grant a declaration, or provide another remedy permitted by law. Some immigration decisions are subject to special restrictions on review.

An applicant should therefore identify the specific legal decision, the responsible authority, the applicable review deadline, and the statutory route available before pursuing a remedy.

15. Critical Evaluation

The proposed doctrine must balance two competing concerns.

On one side, governments have legitimate reasons to verify identity, establish family relationships, conduct legally authorised medical examinations, and protect public health.

On the other side, biological information is unusually sensitive. Its use may reveal information beyond the immediate question under investigation and may affect relatives or other third parties.

The principal danger is biological overreach: using a test for a purpose it cannot reliably establish, treating statistical risk as certainty, or allowing an administrative classification to replace an individualised legal assessment.

Three further limitations deserve attention.

First, scientific evidence changes. A test that is useful for one purpose may be unsuitable for another, and the interpretation of results may change as scientific knowledge develops.

Second, privacy protections differ across jurisdictions. A collection method permitted under one immigration statute may be unlawful under another jurisdiction's privacy or constitutional rules.

Third, immigration decisions involve different legal contexts. Establishing a biological relationship is not the same as predicting a future illness, and neither is equivalent to determining whether a person poses a public-health risk.

The doctrine is therefore most useful as a framework for disciplined legal analysis rather than as a universal rule that all biomarker-based immigration decisions are either lawful or unlawful.

16. Conclusion

Biomarker Immigration Accountability Doctrine and Governance concerns the legal limits and institutional responsibilities associated with using biological information in immigration administration.

The most relevant authorities demonstrate complementary principles:

1. India — Justice K.S. Puttaswamy v. Union of India (2017): Constitutional privacy, informational autonomy, legality, and proportionality.
2. India — Mr. X v. Hospital Z (1998): Medical confidentiality and the competing interests that may justify disclosure.
3. Canada — Hilewitz v. Canada (2005): Individualised assessment in medical inadmissibility decisions.
4. Canada — Chesters v. Canada (2002): Medical assessment, excessive-demand reasoning, and constitutional challenges.
5. Canada — Rashid v. Canada (2010): Medical inadmissibility based on an individual assessment of anticipated health-service demands.
6. United States — Matter of Ruzku (2016): Evaluation of DNA evidence alongside the totality of the evidence.
7. United States — Muthana v. Mullin (2026): Immigration litigation involving biological relationship evidence and procedural issues.
8. European Court of Human Rights — S. and Marper v. United Kingdom (2008): Privacy implications of retaining genetic samples and DNA profiles.
9. European Court of Human Rights — Z v. Finland (1997): Confidentiality of sensitive medical information.
10. Canada — CBSA genetic-genealogy investigation: Regulatory accountability for genetic-information collection, authorisation, disclosure, and transparency.

The overarching principle is that biological evidence must remain subject to law, scientific scrutiny, privacy protection, procedural fairness, and appropriate institutional oversight.

A government may have legitimate reasons to use biological information in immigration administration. However, the existence of a biomarker does not by itself establish that a person should be admitted, refused entry, detained, or removed. The legal consequences must follow from the applicable law and a defensible assessment of the evidence.

Research note: The authorities above arise from different legal systems and do not all concern medical biomarkers directly. They should be distinguished according to their actual subject matter and precedential status when used in academic writing or litigation.